Sepsis, Neonatal
Basics
Basics
Basics
Description
Description
Description
- Clinical syndrome characterized by systemic infection occurring within the first 28 days of life
- Early-onset sepsis (EOS) and late-onset sepsis (LOS) occur within and following the first 72 hours of life, respectively.
- Some consider infection within the first 7 days of life early onset, especially in term infants who are not hospitalized.
Epidemiology
Epidemiology
Epidemiology
- EOS: 1/1,000 live births in the United States. Incidence is much higher among very-low-birth-weight (VLBW) neonates.
- LOS: Among febrile neonates presenting to the emergency department, approximately 12% are diagnosed with a serious bacterial infection. Incidence among hospitalized preterm infants is inversely associated with birth weight.
Risk Factors
Risk Factors
Risk Factors
- Neonates are at increased risk for infection due to their immature immune system (permitting relative immune tolerance) and their developing, under-keratinized cutaneous barrier.
- Maternal factors:
- Low socioeconomic status
- Illicit substance use
- Inadequate or no prenatal care
- Poor maternal nutrition
- Intra-amniotic procedures
- Preterm labor, prolonged or premature rupture of membranes
- Chorioamnionitis or “intrauterine inflammation, infection, or both” (III, “triple I”; a new term describing the heterogenous conditions labeled previously as chorioamnionitis)
- Presence of cervical cerclage
- Septic/traumatic delivery
- Peripartum infection, including urinary tract infections (UTIs)
- Group B Streptococcus (GBS) colonization
- Ingestion of contaminated foods during pregnancy (Listeria)
- Infant factors:
- Male sex
- Prematurity or low birth weight
- Low Apgar scores
- Congenital anomalies
- Compromised skin integrity
- Galactosemia (Escherichia coli sepsis)
- Invasive procedures,
- Presence of central line
Genetics
Genetics
Genetics
Single nucleotide polymorphisms (SNPs) in genes involved in inflammation have been linked to increased risk of neonatal sepsis.
General Prevention
General Prevention
General Prevention
- Recognition and treatment of maternal peripartum infections and colonization (i.e., GBS)
- General obstetric practices to reduce risk of chorioamnionitis/III and postnatal clean cord care
- Thermoregulation and early breastfeeding
- Hand hygiene, avoidance of fomites
Pathophysiology
Pathophysiology
Pathophysiology
- EOS: primarily vertical transmission, with ante- or intrapartum acquisition of bacteria colonizing the maternal genitourinary tract
- LOS: primarily due to horizontal transmission or nosocomial infection in hospitalized infants
Etiology
Etiology
Etiology
- EOS:
- GBS is most common (~40%), followed by E. coli (~20–30%), other streptococci (~10%).
- Incidence of GBS disease has decreased since initiation of intrapartum antibiotic prophylaxis (IAP).
- E. coli is the most common pathogen in VLBW infants.
- Overall incidence of Listeria sepsis is low, but it is more common in preterm infants.
- Viral pathogens, including enteroviruses, may present with EOS.
- LOS:
- GBS and E. coli remain important; consider Staphylococcus aureus (up to a quarter methicillin-resistant) and coagulase-negative staphylococci (CoNS), especially in hospitalized infants.
- Pseudomonas aeruginosa carries the highest mortality risk in preterm infants (up to 75%).
- Yeast infections should be considered, with hospitalized preterm infants at greatest risk.
- Viral pathogens, including enteroviruses, may present with LOS; viral meningitis is more common in the late-onset period.
- Perinatally acquired HSV infection should be considered in neonates at any period during the 1st month of age.
Commonly Associated Conditions
Commonly Associated Conditions
Commonly Associated Conditions
- Meningitis: Up to a quarter of neonates with bacteremia have meningitis.
- Pneumonia
- UTI
- Omphalitis
- Osteomyelitis
- Severe hyperbilirubinemia
- Persistent pulmonary hypertension of the newborn (PPHN)
- Patent ductus arteriosus (PDA)
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2025 Unbound Medicine, Inc. All rights reserved